Related Experiment Video
Updated: Feb 10, 2026

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
Published on: August 25, 2014
Public interest and expectations concerning commercial genotyping and genetic risk assessment
Oksana A Makeeva1, Valentina V Markova1, Valery P Puzyrev1
1Research Institute of Medical Genetics of The Siberian Branch of The Russian Academy of Medical Sciences, 10 Nab. Ushaiky, Tomsk 634050, Russia. oksana.makeeva@medgenetics.ru.
Abstract:
In contrast to the modest progress made in the interpretation and clinical application of genomic data, genotyping technologies have experienced great progress. Genotyping costs are progressively decreasing making individual genotyping more commonly available. Financial availability of individual genome analysis and the strong desire of many people to know about their individual genomic characteristics, promotes the marketing of genetic tests of variable predictive value directly to the public. A survey of 2000 Russian respondents revealed very positive attitudes and beliefs towards these genetic developments: 85% of surveyed individuals would like to have their genetic risk for avoidable diseases estimated, and 89% responded stating that they would try to change their lifestyle by giving up bad habits, following a recommended diet or taking medications if a high risk of disease was identified. It is believed that with time, validated genetic information will find its rightful place in medicine, by supplementing phenotypic clinical data with validated genetic interpretations.
Related Concept Videos
Expected Value
Design Example: Analyzing Capacity Contours for Flood Risk Assessment
Determination of Expected Frequency
Genetic Lingo
Relative Risk
Genetics of Speciation

